Heterocyclic aspartyl protease inhibitors and their combination with cholinesterase inhibitors or muscarinic antagonists

摘要

Disclosed are heterocyclic compounds represented by structural formula (I), a stereoisomer, tautomer, a pharmaceutically acceptable salt and solvate thereof. These heterocyclic compounds are suitable for inhibiting aspartyl protease, and are particularly used for the treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula (I) in combination with a cholinesterase inhibitor or a muscarinic antagonist.